Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

927
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
927
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

749
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
749
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

2.8K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.8K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

2.5K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.5K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.2K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PARQ: A Complexity-Consensus Aware Automatic Assessment of Motor Disease Severity in Parkinson's Disease.

Research square·2026
Same author

Enhancing Neurologic Clinical Competency-Implementing Competency-based Medical Education and Workplace-based Assessments in a Neurology Clerkship.

Seminars in neurology·2025
Same author

Diabetic Neuropathies.

Muscle & nerve·2025
Same author

Use of botulinum toxin in the management of dystonia in Parkinson's disease.

Frontiers in neuroscience·2024
Same author

Botulinum toxin treatment in parkinsonism.

Journal of the neurological sciences·2023
Same author

Targeting α-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics.

Drugs·2019

Related Experiment Video

Updated: Nov 21, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

23.9K

Botulinum Toxin in Movement Disorders: An Update.

Charenya Anandan1, Joseph Jankovic1

  • 1Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.

Toxins
|January 12, 2021
PubMed
Summary

Botulinum toxin (BoNT) is a safe and effective treatment for various neurological movement disorders, including dystonia and Parkinson's disease symptoms. Recent research explores its potential for central nervous system applications and neurodegenerative disorders.

Keywords:
Parkinson’s diseasebotulinum toxinbruxismdyskinesiadystoniamovement disordersmyoclonusrestless legs syndrometicstremors

More Related Videos

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.3K
A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.6K

Related Experiment Videos

Last Updated: Nov 21, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

23.9K
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.3K
A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.6K

Area of Science:

  • Neurology
  • Pharmacology
  • Biotechnology

Background:

  • Botulinum toxin (BoNT) was first approved in 1989 for facial spasms.
  • It is now a versatile therapeutic for numerous neurological and non-neurological conditions.
  • BoNT's applications have expanded from muscle relaxation to potential central nervous system treatments.

Purpose of the Study:

  • To provide an update on recent advances in botulinum toxin research.
  • To focus on novel applications of BoNT in treating movement disorders.
  • To critically review evidence-based clinical trials and innovative pilot studies.

Main Methods:

  • Comprehensive literature review.
  • Analysis of evidence-based clinical trials.
  • Highlighting recent innovative pilot studies.

Main Results:

  • BoNT is effective for dystonia, bruxism, tremors, tics, myoclonus, restless legs syndrome, tardive dyskinesia, and Parkinson's disease symptoms.
  • Research is expanding to explore BoNT's central nervous system applications.
  • BoNT is considered a safe therapeutic agent when administered by experienced clinicians.

Conclusions:

  • Botulinum toxin (BoNT) continues to demonstrate efficacy in treating a wide range of movement disorders.
  • Emerging research suggests potential for BoNT in treating neurodegenerative conditions via central nervous system applications.
  • The review underscores the safety and evolving therapeutic landscape of BoNT.